Linezolid B. Braun Melsungen Ag (Linezolid)

Linezolid works by binding to the bacterial 50S ribosomal subunit, blocking the formation of the initiation complex needed for protein synthesis. This inhibition halts bacterial growth, producing a bacteriostatic effect against most Gram‑positive organisms, including resistant strains such as MRSA and VRE.

The specific dose of linezolid is determined by the prescribing clinician based on the infection type, severity, and patient characteristics. In adult practice, a common regimen is 600 mg administered intravenously every 12 hours, but the exact schedule must be set by a qualified healthcare professional.

Safety data for linezolid during pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. Use is only recommended when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and it should be prescribed with caution.

To order, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets, and will request trade or institutional credentials before providing pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Linezolid is often compared with vancomycin, another agent for Gram‑positive infections. Unlike vancomycin, linezolid is available in an oral formulation and has excellent lung penetration, but it carries a higher risk of hematologic toxicity and serotonin syndrome. Choice depends on infection site, pathogen susceptibility, patient renal function and safety profile.

Linezolid injectable solution should be stored at 2‑8 °C (refrigerated). Keep the product in its original container, protect it from light, and avoid freezing or shaking. If temporary storage at room temperature is unavoidable, limit exposure to no more than 24 hours.

Linezolid is administered intravenously as a sterile solution. The infusion is typically given over 30‑60 minutes, depending on institutional protocols. Administration should follow aseptic technique, and the line must be flushed before and after the infusion to ensure complete delivery of the dose.

Serious risks include thrombocytopenia, which may lead to bleeding; peripheral neuropathy, which can become irreversible; serotonin syndrome when combined with serotonergic agents; and rare metabolic disturbances such as lactic acidosis. Patients should be monitored regularly for blood counts, neurological symptoms and signs of serotonin excess.

Linezolid should not be used in individuals with known hypersensitivity to linezolid or any component of the formulation. It is also contraindicated in patients currently receiving monoamine oxidase inhibitors (MAOIs) and should be avoided in those taking serotonergic medications without careful risk assessment.